Oxis International, operating as GT Biopharma, is at the forefront of immuno-oncology, focusing on the development of innovative therapies utilizing its proprietary NK cell engager technology, known as TriKE®. This platform is designed to create targeted immunotherapeutic agents that engage natural killer (NK) cells and cancer cells simultaneously, enhancing the selective destruction of cancerous cells. The TriKE® agents are engineered from a bispecific antibody framework and incorporate camelid nanobody technology, which allows for the precise targeting of tumor cells while minimizing adverse effects. The TriKE® construct consists of three functional components: a camelid nanobody that binds to the CD16 receptor on NK cells, a single-chain variable fragment (scFv) that recognizes specific tumor markers, and a human interleukin-15 (IL-15) cross-linker that activates NK cells and promotes their proliferation.

The TriKE® technology addresses critical aspects of the immune response against cancer, including antibody-dependent cellular cytotoxicity (ADCC) and the recruitment of additional NK cells through IL-15 signaling. This innovative approach not only enhances the efficacy of NK cells in targeting tumors but also reduces the risk of systemic cytokine release syndrome, a common side effect associated with traditional cytokine therapies. GT Biopharma's clinical pipeline includes several TriKE® candidates aimed at treating various hematological malignancies and solid tumors, demonstrating the versatility and potential of this technology in advancing cancer treatment.

United States

Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE) platform technology. (NASDAQ: GTBP)

Oxis International(GT Biopharma)

Company Details